帕立骨化醇治疗甲状旁腺功能亢进疗效观察

Clinical observation of paricalcitol treatment in hyperparathyroidism

目的:探讨帕立骨化醇在治疗甲状旁腺功能亢进患者中的临床疗效。方法:回顾筛选27例确诊为甲状旁腺功能亢进的维持性血液透析患者,根据个体化原则注射帕立骨化醇,观察疗效改变。结果:27例患者初始治疗有效率为66.67%,治疗后iPTH较基线水平下降33.10%,差异有统计学意义(P<0.001);血钙平均水平较前升高,差异有统计学意义(P<0.001)。结论:帕立骨化醇对血液透析合并甲状旁腺功能亢进的患者治疗有效,使iPTH水平明显下降,但可能存在发生高钙血症的风险。

Objective:This study aimed to evaluate clinical effect of Paricalcitol treatment in patients with hyperparathyroidism (HPT) undergoing hemodialysis.Methods:Twenty-seven patients with maintenance hemodialysis who were diagnosed as hyperparathyroidism by clinical symptoms were screened retrospectively,and Paricalcitol treatment was injected according to the individual principle to observe the curative effect.Results:The initial response rate of the 27 patients was 66.67%,after treatment,iPTH decreased by 33.10% from the baseline level,which was statistically significant(P<0.001).The mean serum calcium level was higher than before,and the difference was statistically significant(P<0.001).Conclusion:Paricalcitol treatment can effectively improve hyperparathyroidism in hemodialysis patients and significantly reduce iPTH level,whereas it may increase the risk of hypercalcemia.